Richard Bungay
Chief Executive Officer chez DIUL GROUP
Fortune : 7 100 $ au 31/03/2024
Profil
Richard Edward Bungay is currently the Chief Executive Officer at Diurnal Group Ltd., the Chief Executive Officer at Imophoron Ltd., the Director at Chroma Therapeutics Ltd., the Secretary & Director at Macrotarg Ltd., the Non-Executive Director at Nasdaq Corporate Solutions International Ltd., the Non-Executive Director at Cambridge Cognition Holdings Plc, the Secretary & Director at Diurnal Ltd., and the Director at Monument Therapeutics Ltd.
Previously, he worked as the Finance Director-Respiratory & Inflammation Area at AstraZeneca PLC from 1998 to 2000, the Director-Corporate Communications at Celltech Group Plc, the Chief Financial Officer & Non-Executive Director at Glide Pharmaceutical Technologies Ltd., the Chief Financial Officer at Verona Pharma Plc from 2013 to 2014, and the Chief Operating & Financial Officer at Mereo BioPharma Group Plc.
He obtained his undergraduate degree from The University of Nottingham.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/05/2023 | 10 000 ( 0,03% ) | 7 100 $ | 31/03/2024 |
Postes actifs de Richard Bungay
| Sociétés | Poste | Début |
|---|---|---|
| DIUL GROUP | Chief Executive Officer | 04/04/2022 |
| CAMBRIDGE COGNITION HOLDINGS PLC | Director/Board Member | 14/09/2020 |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Director/Board Member | 01/10/2004 |
Nasdaq Corporate Solutions International Ltd.
 Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Nasdaq Corporate Solutions International Ltd. develops and manages software for corporate communications and reputation management solutions. The company was founded in and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Diurnal Ltd.
 Diurnal Ltd. Pharmaceuticals: MajorHealth Technology Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The private company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions. | Director/Board Member | 18/01/2017 |
Macrotarg Ltd.
 Macrotarg Ltd. BiotechnologyHealth Technology Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK. | Director/Board Member | 04/05/2011 |
Monument Therapeutics Ltd.
 Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | Director/Board Member | - |
Imophoron Ltd.
 Imophoron Ltd. BiotechnologyHealth Technology Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022. | Chief Executive Officer | 14/11/2022 |
Anciens postes connus de Richard Bungay
| Sociétés | Poste | Fin |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Director of Finance/CFO | 13/01/2017 |
| ░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░ ░░░ | ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | - |
Formation de Richard Bungay
| The University of Nottingham | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| VERONA PHARMA PLC | Health Technology |
| CAMBRIDGE COGNITION HOLDINGS PLC | Technology Services |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| Entreprise privées | 9 |
|---|---|
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Glide Pharmaceutical Technologies Ltd.
 Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Health Technology |
Diurnal Group Ltd.
 Diurnal Group Ltd. Pharmaceuticals: MajorHealth Technology Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. It focuses on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The company was founded by Richard John Martin Ross in 2004 and is headquartered in Cardiff, the United Kingdom. | Health Technology |
Macrotarg Ltd.
Macrotarg Ltd. BiotechnologyHealth Technology Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK. | Health Technology |
Nasdaq Corporate Solutions International Ltd.
Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Nasdaq Corporate Solutions International Ltd. develops and manages software for corporate communications and reputation management solutions. The company was founded in and is headquartered in London, the United Kingdom. | Technology Services |
Diurnal Ltd.
Diurnal Ltd. Pharmaceuticals: MajorHealth Technology Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The private company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions. | Health Technology |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | Health Technology |
Imophoron Ltd.
Imophoron Ltd. BiotechnologyHealth Technology Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022. | Health Technology |
